Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bronx, NY
NPI
1275850208
Since 2010
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
3050 Corlear Ave, Suite 204
Bronx, NY, 10463
Phone (646) 317-0129
Groups this clinician bills Medicare through
Medicare paid, 2024
$115K
2,303 services
Medicare patients, 2024
682
Average age 74
Drug cost, 2024
$1.2M
1,513 prescriptions
Company payments, 2025
$756
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jessica R Starr was code J0897 (injection, denosumab, 1 mg), 1,140 times for 16 patients. In total Jessica R Starr billed 2,303 services in 13 codes, and Medicare paid $115K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,140 | 16 | $18.70 | $21K |
| 99214 Office E&M - Established | Office | 507 | 466 | $99.16 | $50K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 395 | 369 | $13.99 | $5,525 |
| 99205 Office E&M - New | Office | 188 | 188 | $166.35 | $31K |
| 99204 Office E&M - New | Office | 39 | 39 | $129.08 | $5,034 |
| 96372 Injection Administration | Office | 24 | 22 | $11.63 | $279 |
By year: 2022 $180K for 5,192 services; 2023 $218K for 5,001 services; 2024 $115K for 2,303 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jessica R Starr prescribed most often to Medicare patients was Alendronate Sodium, with 433 prescriptions and refills. In total Jessica R Starr wrote 1,513 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Alendronate Sodium Generic | 433 | 1,002 | 127 | $4,049 |
| Teriparatide Generic | 198 | 200 | 36 | $509K |
| Levothyroxine Sodium Generic | 138 | 361 | 45 | $1,484 |
| Forteo Teriparatide | 76 | 76 | 11 | $337K |
| Mounjaro Tirzepatide | 70 | 83 | Under 11 | $84K |
| Synthroid Levothyroxine Sodium | 64 | 174 | 22 | $4,603 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 47 | 107 | 21 | $1,940 |
| Tymlos Abaloparatide | 38 | 38 | Under 11 | $106K |
| Metformin Hcl Generic | 33 | 89 | 12 | $239 |
| Progesterone Progesterone, Micronized | 30 | 68 | Under 11 | $532 |
| Metformin Hcl Er Metformin Hcl | 28 | 60 | Under 11 | $641 |
| Raloxifene Hcl Generic | 27 | 77 | Under 11 | $1,226 |
| Jardiance Empagliflozin | 25 | 27 | Under 11 | $16K |
| Risedronate Sodium Generic | 19 | 29 | Under 11 | $858 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 19 | 49 | 13 | $668 |
Brand drugs: 635 claims; generic drugs: 774 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jessica R Starr $756 ($756 in general payments such as food, travel and fees) from 10 companies. The largest payer was Amgen Inc. with $140.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 6 | $140 |
| Radius Health, Inc. | 4 | $104 |
| Kyowa Kirin, Inc. 4151.T | 4 | $104 |
| Lilly USA, LLC LLY | 4 | $82.48 |
| Alvogen Inc | 4 | $74.27 |
| Corcept Therapeutics CORT | 3 | $69.03 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $56.59 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $54.52 |
| Novo Nordisk Inc NVO | 2 | $46.79 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $24.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.